Digene Taps Cytyc's 110 Physician Reps For Hybrid Capture 2 HPV Test
This article was originally published in The Gray Sheet
Cytyc's 110-person direct sales force focusing on the physician market will offer Digene's Hybrid Capture 2 test for human papilloma virus in conjunction with Cytyc's ThinPrep automated Pap test under a Jan. 18 exclusive co-marketing agreement between the firms.
You may also be interested in...
The payback on Cytyc's $554 mil. acquisition of Digene could get a quick boost from Digene's pending primary screening indication for DNA Pap for cervical cancer
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.